TerminatedNCT01717040
Pioglitazone for the Treatment of Depression in bipolarity
Medication studyAges 18+United States
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- ClevelandSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateSeptember 2012
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 37
- Sponsor
- University Hospitals Cleveland Medical Center
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT01717040
- Official title
Show the full official title
Double-Blind, Placebo-Controlled Trial of Pioglitazone for Bipolar Depression
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cleveland
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University Hospitals Cleveland Medical Center, a university.
Does this study involve medication?
Yes. The study involves medication, including Pioglitazone and Placebo.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as terminated.
